Botanix Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Botanix Pharmaceuticals yıllık ortalama 10.3% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 35.1% annual. Gelirler azalıyor .

Anahtar bilgiler

10.3%

Kazanç büyüme oranı

20.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	31.2%
Gelir büyüme oranı	-25.0%
Özkaynak getirisi	-12.8%
Net Marj	-670.2%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Botanix Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CHIA:BOT Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	2	-14	11
31 Mar 24	1	-12	9
31 Dec 23	0	-10	7
30 Sep 23	2	-10	6
30 Jun 23	4	-9	6
31 Mar 23	5	-10	6
31 Dec 22	6	-11	6
30 Sep 22	5	-12	5
30 Jun 22	3	-13	5
31 Mar 22	1	-12	4
31 Dec 21	0	-11	4
30 Sep 21	3	-7	3
30 Jun 21	7	-3	3
31 Mar 21	7	-6	4
31 Dec 20	7	-9	5
30 Sep 20	7	-13	8
30 Jun 20	8	-17	10
31 Mar 20	8	-18	10
31 Dec 19	8	-20	10
30 Sep 19	6	-18	7
30 Jun 19	5	-17	5
31 Mar 19	5	-15	3
31 Dec 18	5	-13	2
30 Sep 18	3	-12	2
30 Jun 18	2	-11	2
31 Mar 18	2	-8	2
31 Dec 17	2	-6	2
30 Sep 17	1	-5	1
30 Jun 17	0	-5	1
31 Dec 16	0	-3	1

Kaliteli Kazançlar: BOT şu anda kârlı değil.

Büyüyen Kar Marjı: BOT şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BOT kârlı değildir, ancak son 5 yılda zararlarını yılda 10.3% oranında azaltmıştır.

Büyüme Hızlandırma: BOT 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BOT kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 26.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BOT hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -12.76% ) sahiptir.

Botanix Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2024 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in FY 2023)

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Recent updates

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Full year 2024 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in FY 2023)

Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.

New major risk - Financial position

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin